Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

LC-MS/MS Method Development and Validation of Lenvatinib and its Related Impurities in Rat Plasma: Application to a Pharmacokinetic Study

Author(s): Subrahmanyam Talari, Anuradha Vejendla*, S.N. Murthy Boddapati and Johar Kalidindi

Volume 18, Issue 6, 2022

Published on: 01 April, 2022

Page: [614 - 628] Pages: 15

DOI: 10.2174/1573412918666220330004440

Price: $65

Abstract

Background: Lenvatinib is a potent drug utilized in the medication of thyroid cancer and it acts as a tyrosine kinase inhibitor. Thus, the development and validation of Lenvatinib and allied impurities in rat plasma, and its pharmacokinetic study, are one of the most significant areas of modern pharmaceutical analysis.

Objective: The current study conducts bioanalytical system validation and pharmacokinetic analysis of Lenvatinib and associated impurities in rat plasma with LC-MS/MS.

Methods: The current study involves bioanalytical system validation and pharmacokinetic analysis of Lenvatinib and associated impurities in rat plasma using LC-MS/MS. Gradient elution of Lenvatinib with a flow rate of 1 mL/min and an X-Bridge phenyl column (150x4.6 mm, 3.5μ) was used in the optimized process. In this method, buffer (1 mL formic acid in 1 liter of water) and acetonitrile mixture was used as the mobile phase.

Results: By using Carfilzomib as the internal norm and impurity-4 as the active metabolite and 30 minute run time, Lenvatinib and its associated impurities were separated. The linearity was in the range of 10 percent to 200 percent of rat plasma, and each analyte R2 value was found to be 0.999.

Conclusion: This work indicates that all parameters, such as precision, recovery, accuracy, and stability, were achieved as per USFDA guidelines. This approach can be used to investigate Lenvatinib impurities and conduct pharmacokinetic studies involving rat plasma.

Keywords: Rat plasma, LC-MS/MS, lenvatinib, impurities, development, validation.

« Previous Next »
Graphical Abstract

[1]
Wagner, A.D.; Syn, N.L.; Moehler, M.; Grothe, W.; Yong, W.P.; Tai, B.C.; Ho, J.; Unverzagt, S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev., 2017, 8, CD004064.
[PMID: 28850174]
[2]
Gerber, D.E. Targeted therapies: A new generation of cancer treatments. Am. Fam. Physician, 2008, 77(3), 311-319.
[PMID: 18297955]
[3]
Lamartina, L.; Grani, G.; Durante, C.; Filetti, S. Recent advances in managing differentiated thyroid cancer. F1000 Res., 2018, 7, 86.
[http://dx.doi.org/10.12688/f1000research.12811.1] [PMID: 29399330]
[4]
Carling, T.; Udelsman, R. Thyroid cancer. Annu. Rev. Med., 2014, 65, 125-137.
[http://dx.doi.org/10.1146/annurev-med-061512-105739] [PMID: 24274180]
[5]
Pacini, F.; Castagna, M.G.; Brilli, L.; Pentheroudakis, G. Thyroid cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 23(Suppl. 7), vii110-vii119.
[http://dx.doi.org/10.1093/annonc/mds230] [PMID: 22997443]
[6]
Gross, S.; Rahal, R.; Stransky, N.; Lengauer, C.; Hoeflich, K.P. Targeting cancer with kinase inhibitors. J. Clin. Invest., 2015, 125(5), 1780-1789.
[http://dx.doi.org/10.1172/JCI76094] [PMID: 25932675]
[7]
Jänne, P.A.; Gray, N.; Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov., 2009, 8(9), 709-723.
[http://dx.doi.org/10.1038/nrd2871] [PMID: 19629074]
[8]
Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-kinase inhibitor e7080 suppresses lymph node and lung metastases of human mammary breast tumor mda-mb-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res., 2008, 14(17), 5459-5465.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-5270] [PMID: 18765537]
[9]
Hertz, B.E.; Schuller, K.E. Saul hertz, md (1905-1950): A pioneer in the use of radioactive iodine. Endocr. Pract., 2010, 16(4), 713-715.
[http://dx.doi.org/10.4158/EP10065.CO] [PMID: 20350908]
[10]
Joshi, S.; Ettinger, L.; Liebman, S.E. Plant-based diets and hypertension. Am. J. Lifestyle Med., 2019, 14(4), 397-405.
[http://dx.doi.org/10.1177/1559827619875411] [PMID: 33281520]
[11]
Viera, A.J. Screening for hypertension and lowering blood pressure for prevention of cardiovascular disease events. Med. Clin. North Am., 2017, 101(4), 701-712.
[http://dx.doi.org/10.1016/j.mcna.2017.03.003] [PMID: 28577621]
[12]
Arasaradnam, R.P.; Brown, S.; Forbes, A.; Fox, M.R.; Hungin, P.; Kelman, L.; Major, G.; O’Connor, M.; Sanders, D.S.; Sinha, R.; Smith, S.C.; Thomas, P.; Walters, J.R.F. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology. Gut, 2018, 67(8), 1380-1399.
[13]
Mills, R.J.; Young, C.A.; Pallant, J.F.; Tennant, A. Development of a patient reported outcome scale for fatigue in multiple sclerosis: The neurological fatigue index (NFI-MS). Health Qual. Life Outcomes, 2010, 8, 22.
[http://dx.doi.org/10.1186/1477-7525-8-22] [PMID: 20152031]
[14]
Owen, J.B. Weight control and appetite-a genetic perspective. Clin. Nutr., 1990, 9(5), 291-293.
[http://dx.doi.org/10.1016/0261-5614(90)90039-U] [PMID: 16837373]
[15]
Laurent, S. Antihypertensive drugs. Pharmacol. Res., 2017, 124, 116-125.
[http://dx.doi.org/10.1016/j.phrs.2017.07.026] [PMID: 28780421]
[16]
Estcourt, L.J.; Malouf, R.; Hopewell, S.; Doree, C.; Van Veen, J. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. Cochrane Database Syst. Rev., 2018, 4, CD011980.
[http://dx.doi.org/10.1002/14651858.CD011980.pub3] [PMID: 29709077]
[17]
Falk, S.; Uldall, M.; Heegaard, A.M. The role of purinergic receptors in cancer-induced bone pain. J. Osteoporos., 2012, 2012, 758181.
[http://dx.doi.org/10.1155/2012/758181] [PMID: 23091774]
[18]
Gillis, A.M. Heart rhythm journal celebrates 10 years. Heart Rhythm, 2013, 10(5), 619.
[http://dx.doi.org/10.1016/j.hrthm.2013.03.044]
[19]
Groot, J.A.N.; Ten Bokum, L.; van den Oever, H.L.A.; Antonius, H.L. Late presentation of Torsades de Pointes related to fluoxetine following a multiple drug overdose. J. Intensive Care, 2018, 6, 59.
[http://dx.doi.org/10.1186/s40560-018-0329-1] [PMID: 30214811]
[20]
zygmunt, T; Gay, C.M; Blondelle, J; Singh, M.K; Flaherty, K.M; Means, P.C Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev. Cell, 2011, 21(2), 301-314.
[http://dx.doi.org/10.1016/j.devcel.2011.06.033] [PMID: 21802375]
[21]
Chae, Y.K.; Ranganath, K.; Hammerman, P.S.; Vaklavas, C.; Mohindra, N.; Kalyan, A.; Matsangou, M.; Costa, R.; Carneiro, B.; Villaflor, V.M.; Cristofanilli, M.; Giles, F.J. Inhibition of the fibroblast Growth Factor Receptor (FGFR) pathway: The current landscape and barriers to clinical application. Oncotarget, 2017, 8(9), 16052-16074.
[http://dx.doi.org/10.18632/oncotarget.14109] [PMID: 28030802]
[22]
Cao, Y.; Cao, R.; Hedlund, E.M.R. R regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. (Berl.), 2008, 86(7), 785-789.
[http://dx.doi.org/10.1007/s00109-008-0337-z] [PMID: 18392794]
[23]
Shewry, P.R.; Pandya, M.J. The 2s albumin storage proteins. seed proteins; Springer: Amseterdam, Netherlands, 1999, pp. 563-586.
[http://dx.doi.org/10.1007/978-94-011-4431-5_24]
[24]
Strelevitz, T.J.; Orozco, C.C.; Obach, R.S. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: Estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab. Dispos., 2012, 40(7), 1441-1448.
[http://dx.doi.org/10.1124/dmd.112.045195] [PMID: 22522748]
[25]
Obach, R.S. Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy. Pharmacol. Rev., 2013, 65(2), 578-640.
[http://dx.doi.org/10.1124/pr.111.005439] [PMID: 23406671]
[26]
Radzicka, A.; Wolfenden, R. Transition state and multisubstrate analog inhibitors. Methods Enzymol., 1995, 249, 284-312.
[http://dx.doi.org/10.1016/0076-6879(95)49039-6] [PMID: 7791615]
[27]
Ogawa-Morita, T.; Sano, Y.; Okano, T.; Fujii, H.; Tahara, M.; Yamaguchi, M.; Minami, H. Validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analysis of lenvatinib in human plasma. Int. J. Anal. Chem., 2017, 2017, 2341876.
[http://dx.doi.org/10.1155/2017/2341876] [PMID: 28680445]
[28]
Dubbelman, A.C.; Rosing, H.; Thijssen, B.; Gebretensae, A.; Lucas, L.; Chen, H.; Shumaker, R.; Schellens, J.H.; Beijnen, J.H. Development and validation of LC-MS/MS assays for the quantification of e7080 and metabolites in various human biological matrices. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2012, 25(3), 887-888.
[http://dx.doi.org/10.1016/j.jchromb.2012.01.004] [PMID: 22309776]
[29]
Rao, K.P. Related substances method development and validation of an LCMS/MS method for quantification of selexipag and its related impurities in rat plasma and its application to pharmacokinetic studies. SN Appl. Sci., 2021, 3, 321.
[http://dx.doi.org/10.1007/s42452-021-04219-x]

Rights & Permissions Print Cite
Article Metrics
32
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy